ES2158452T3 - Uso de agonistas y antagonistas de estrogenos en la fabricacion de un medicamento para el tratamiento de la ateroesclerosis, independientemente de la disminucion de lipidos. - Google Patents

Uso de agonistas y antagonistas de estrogenos en la fabricacion de un medicamento para el tratamiento de la ateroesclerosis, independientemente de la disminucion de lipidos.

Info

Publication number
ES2158452T3
ES2158452T3 ES97308862T ES97308862T ES2158452T3 ES 2158452 T3 ES2158452 T3 ES 2158452T3 ES 97308862 T ES97308862 T ES 97308862T ES 97308862 T ES97308862 T ES 97308862T ES 2158452 T3 ES2158452 T3 ES 2158452T3
Authority
ES
Spain
Prior art keywords
aterosclerosis
agronists
strogens
antagonists
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97308862T
Other languages
English (en)
Inventor
Robert Joseph Aiello
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PFIZER
Pfizer Inc
Original Assignee
PFIZER
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PFIZER, Pfizer Inc filed Critical PFIZER
Application granted granted Critical
Publication of ES2158452T3 publication Critical patent/ES2158452T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A47—FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
    • A47J—KITCHEN EQUIPMENT; COFFEE MILLS; SPICE MILLS; APPARATUS FOR MAKING BEVERAGES
    • A47J47/00—Kitchen containers, stands or the like, not provided for in other groups of this subclass; Cutting-boards, e.g. for bread
    • A47J47/02—Closed containers for foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)

Abstract

SE DESCRIBE EL USO DE UN COMPUESTO DE FORMULA (I), EN LA CUAL A ES CH SUB,2} O NR, EN LA CUAL R ES H O ALQUILO C SUB,1} C SUB,6}; B, D Y E SON CADA UNO CH O N; Y, Z SUP,1} Y G SON CIERTOS SUSTITUYENTES MENCIONADOS; Y E ES 0, 1 O 2; PARA LA PREPARACION DE UN MEDICAMENTO PARA TRATAR LA ATEROSCLEROSIS.
ES97308862T 1996-11-15 1997-11-05 Uso de agonistas y antagonistas de estrogenos en la fabricacion de un medicamento para el tratamiento de la ateroesclerosis, independientemente de la disminucion de lipidos. Expired - Lifetime ES2158452T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3127396P 1996-11-15 1996-11-15

Publications (1)

Publication Number Publication Date
ES2158452T3 true ES2158452T3 (es) 2001-09-01

Family

ID=21858549

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97308862T Expired - Lifetime ES2158452T3 (es) 1996-11-15 1997-11-05 Uso de agonistas y antagonistas de estrogenos en la fabricacion de un medicamento para el tratamiento de la ateroesclerosis, independientemente de la disminucion de lipidos.

Country Status (17)

Country Link
US (1) US6034102A (es)
EP (1) EP0842661B1 (es)
JP (1) JP3287793B2 (es)
KR (1) KR100367793B1 (es)
AT (1) ATE202702T1 (es)
AU (1) AU740378B2 (es)
CA (1) CA2221114C (es)
DE (1) DE69705480T2 (es)
DK (1) DK0842661T3 (es)
ES (1) ES2158452T3 (es)
GR (1) GR3036455T3 (es)
HU (1) HU223942B1 (es)
IL (1) IL122123A (es)
MY (1) MY114586A (es)
NZ (1) NZ329174A (es)
PT (1) PT842661E (es)
ZA (1) ZA9710292B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL126447A (en) * 1998-10-04 2004-09-27 Vascular Biogenics Ltd An immune preparation that confers tolerance in oral administration and its use in the prevention and / or treatment of atherosclerosis
US20050197283A1 (en) * 1998-10-04 2005-09-08 Vascular Biogenics Ltd. Compositions containing beta 2-glycoprotein I for the prevention and/or treatment of vascular disease
US6331562B1 (en) 1998-12-30 2001-12-18 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
US6291456B1 (en) 1998-12-30 2001-09-18 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
US6593322B1 (en) 1999-03-17 2003-07-15 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
CA2367895A1 (en) 1999-03-17 2000-09-21 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
CO5170459A1 (es) * 1999-06-01 2002-06-27 Pfizer Prod Inc Terapia transdermica con agonistas-antagonistas de estrogenos len-ol, administrados mediante medios transdermicos
EP1113007A1 (en) * 1999-12-24 2001-07-04 Pfizer Inc. Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
AU785199B2 (en) * 2000-06-01 2006-11-02 Watson Pharmaceuticals, Inc. Transdermal delivery of lasofoxifene
CA2420944A1 (en) 2000-08-30 2002-03-07 Chemocentryx, Inc. Inhibition of cmv infection and dissemination
TWI303990B (en) 2000-10-17 2008-12-11 Pfizer Prod Inc New use of estrogen agonists/antagonists for improving vascular health
MXPA03004517A (es) 2000-11-24 2004-03-26 Vascular Biogenics Ltd Metodos que emplean y composiciones que contienen fosfolipidos oxidados definidos para la prevencion y tratamiento de la arteriosclerosis.
AU2002221116A1 (en) * 2000-12-11 2002-06-24 Takeda Chemical Industries Ltd. Medicinal compositions having improved water-solubility
WO2002062296A2 (en) 2001-02-02 2002-08-15 Chemocentryx, Inc. Methods and compositions useful for stimulating an immune response
ATE439131T1 (de) * 2001-08-30 2009-08-15 Chemocentryx Inc Bicyclische verbindungen als hemmer der chemokin- bindung an us28
AU2005314089B2 (en) * 2004-12-08 2011-03-03 Cedars-Sinai Medical Center Methods for diagnosis and treatment of Crohn's disease
WO2010048415A1 (en) * 2008-10-22 2010-04-29 Cedars-Sinai Medical Center Methods of using jak3 genetic variants to diagnose and predict crohn's disease
WO2006109312A2 (en) * 2005-04-15 2006-10-19 Vascular Biogenics Ltd. Compositions containing beta 2-glycoprotein i-derived peptides for the prevention and/or treatment of vascular disease
US20100021917A1 (en) * 2007-02-14 2010-01-28 Cedars-Sinai Medical Center Methods of using genes and genetic variants to predict or diagnose inflammatory bowel disease
US20100190162A1 (en) * 2007-02-26 2010-07-29 Cedars-Sinai Medical Center Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease
WO2010039931A2 (en) * 2008-10-01 2010-04-08 Cedars-Sinai Medical Center Methods of using il17rd and il23-il17 pathway genes to diagnose crohn's disease
WO2008137762A2 (en) * 2007-05-04 2008-11-13 Cedars-Sinai Medical Center Methods of diagnosis and treatment of crohn's disease
US20100015156A1 (en) * 2007-03-06 2010-01-21 Cedars-Sinai Medical Center Diagnosis of inflammatory bowel disease in children
US8486640B2 (en) 2007-03-21 2013-07-16 Cedars-Sinai Medical Center Ileal pouch-anal anastomosis (IPAA) factors in the treatment of inflammatory bowel disease
WO2008134569A2 (en) * 2007-04-26 2008-11-06 Cedars-Sinai Medical Center Diagnosis and treatment of inflammatory bowel disease in the puerto rican population
WO2010062960A2 (en) 2008-11-26 2010-06-03 Cedars-Sinai Medical Center METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE
WO2010075579A2 (en) 2008-12-24 2010-07-01 Cedars-Sinai Medical Center Methods of predicting medically refractive ulcerative colitis (mr-uc) requiring colectomy
KR20230109779A (ko) 2013-03-27 2023-07-20 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한섬유증 및 염증의 완화 및 반전
EP4105236A1 (en) 2013-07-19 2022-12-21 Cedars-Sinai Medical Center Anti-tl1a (tnfsf15) antibody for treatment of inflammatory bowel disease
KR20180127416A (ko) 2016-03-17 2018-11-28 세다르스-신나이 메디칼 센터 Rnaset2를 통한 염증성 장 질환의 진단 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3046719C2 (de) * 1980-12-11 1983-02-17 Klinge Pharma GmbH, 8000 München 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel
JPH04312526A (ja) * 1991-04-09 1992-11-04 Fujisawa Pharmaceut Co Ltd 骨疾患治療剤
DE4320898A1 (de) * 1993-06-24 1995-01-05 Denecke Rainer Dr Med Vet Präparat zur Therapie und Prophylaxe von Erkrankungen, die bei Imbalancen von Plasmalipiden auftreten
US6756388B1 (en) 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
US5426123A (en) * 1994-05-11 1995-06-20 Eli Lilly And Company Method for lowering serum cholesterol with 1,1,2-triphenylbut-1-ene derivatives
US5441986A (en) * 1994-07-19 1995-08-15 Pfizer Inc. Estrogen agonists as remedies for prostate and cardiovascular diseases
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis

Also Published As

Publication number Publication date
IL122123A0 (en) 1998-04-05
JP3287793B2 (ja) 2002-06-04
KR19980042432A (ko) 1998-08-17
GR3036455T3 (en) 2001-11-30
NZ329174A (en) 2000-10-27
ZA9710292B (en) 1999-05-17
JPH10147527A (ja) 1998-06-02
IL122123A (en) 2001-07-24
PT842661E (pt) 2001-10-30
HU223942B1 (hu) 2005-03-29
EP0842661B1 (en) 2001-07-04
AU740378B2 (en) 2001-11-01
KR100367793B1 (ko) 2003-04-21
EP0842661A2 (en) 1998-05-20
DE69705480T2 (de) 2001-10-31
DE69705480D1 (de) 2001-08-09
DK0842661T3 (da) 2001-09-24
CA2221114C (en) 2003-10-28
ATE202702T1 (de) 2001-07-15
AU4523797A (en) 1998-05-21
HUP9702040A1 (hu) 2000-11-28
HU9702040D0 (en) 1998-01-28
MY114586A (en) 2002-11-30
EP0842661A3 (en) 1998-09-02
US6034102A (en) 2000-03-07
CA2221114A1 (en) 1998-05-15

Similar Documents

Publication Publication Date Title
EA200000592A1 (ru) Азаполициклические соединения, конденсированные с арилом
ATE68495T1 (de) 4,5,6,7-tetrahydro-1h-imidazo(4,5c>pyridinderivate und analoge mit antihypertensiver wirkung.
GT199900070A (es) Derivados de isotiazol, utiles como agentes anticancerosos.
ES2113368T3 (es) Antagonistas de serotonina.
EA199700117A1 (ru) Трициклические бензазепиновые антагонисты вазопрессина, способ их получения, фармацевтическая композиция и способ лечения млекопитающих с использованием трициклических бензазепинов
ES2164657T3 (es) Derivados aza-biciclicos puenteados como antagonistas de la sustancia p.
ES2167377T3 (es) Derivados de piridina farmacologicamente activos y procedimientos para la preparacion de los mismos.
ES2138977T3 (es) Agonistas muscarinicos.
BG101715A (bg) Тетрациклени спиросъединения,метод за тяхното получаване и приложението им като 5нт долу 1d рецепторни антагонисти
AR001413A1 (es) Compuestos triciclicos de carbamato, utiles para la inhibición de la función de la proteina g y paratratamiento de enfermedades proliferativas.
ES2162061T3 (es) Derivados de piperidina como antagonistas de la neuroquinina.
ES2058185T3 (es) Derivados de camptotecina y procedimiento para su preparacion.
SE9702564D0 (sv) New compounds
ES2141787T3 (es) Derivados de la 1,2,3,4-tetrahidro-9-acridinamina.
ES2037670T3 (es) Procedimiento para la preparacion de complejos de (2,2-bis(aminometil)-1,3-propanodiol-n,n') platino.
ATE126205T1 (de) Disubstituierte arylverbindungen welche eine selektive leukotrien-b4 antagonistische aktivität aufweisen.
ES2183923T3 (es) Derivados de cromona.
ATE77234T1 (de) Aromatische verbindungen mit amider struktur, derivate von aminobenzoesaeuren, hydroxybenzoesaeuren, zimtsaeuren, urocansaeuren und benzimidazolen, die uvb und/oder uva absorbieren.
DE68920913D1 (de) Serotonin-Antagonisten.
ES2057341T3 (es) Ciclohexenos substituidos como agentes para el sistema nervioso central.
MX9300250A (es) Metodo para emplear piridobenzodiazepinonas antimuscarinicas m1-selectivas en terapia de miopia axial.
FR2599036B1 (fr) Nouveaux derives de synergistines, leur preparation et les compositions pharmaceutiques qui les contiennent
ES2081834T3 (es) Pirrolidin-2-onas 4-metil y 4-etil sustituidas.
ATE113949T1 (de) Alpha-adrenergische rezeptorantagonisten.
DE69810340D1 (de) Naphtho-imidazo(1,2-a)pyridin derivate, deren herstellung und deren verwendung in der behandlung von störungen des zentralnervensystems

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 842661

Country of ref document: ES